cjc 1295 no dac / ipamorelin blend CJC-1295 no/DAC + 10mg CJC-1295 (no DAC) & Ipamorelin

Studies suggest that Tesamorelin may specifically target the growth hormone-releasing hormone receptor (GHRHR), potentially activating the signaling cascade that leads to growth hormone synthesis and subsequent release

This characteristic makes the formulation valuable for evaluating receptor engagement timing, pathway coordination, and endocrine signaling integration within laboratory research models

For most applications, this tradeoff is worthwhile

Possible areas of exploration: * Recovery during sleep * Deep sleep support * Overnight growth hormone optimization 5

CJC/Ipamorelin Safety Considerations and Contraindications: Peptides are NOT FDA-approved with limited human studies